

<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>FRI MARCH 31 12:00 pm</b>	<b>Registration, Refreshments and View Exhibits</b>
<b>1:00 pm</b>	<b>Opening Comments and Pre-Test</b>
<b>1:20 pm</b>	<b>Review of Viral Hepatitis –HCV</b> <ul style="list-style-type: none"> <li>• Highlight of Pre-Lecture 1</li> <li>• Screening and Treatment of HCV</li> </ul> <b>Clinical Cases and Discussion</b>
<b>2:00 pm</b>	<b>Hepatitis B: Epidemiology, Natural History and Testing</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• Anti-viral therapies of HBV</li> <li>• The growing relationship between HBV and HDV</li> </ul>
<b>2:40pm</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Worldwide perspective and promising research studies</li> <li>• Real world outcome studies on HDV and HEV</li> </ul>
<b>3:00 pm</b>	<b>Afternoon break</b>
<b>3:15 pm</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Clinical cases to illustrate HE and Thrombocytopenia</li> <li>• The liver transplant process and its challenges</li> </ul>
<b>3:45 pm</b>	<b>Hepatocellular Carcinoma (HCC)</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> </ul>
<b>4:15 pm</b>	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• <b>A case-based approach to HCC treatment</b></li> <li>• Current FDA-Approved Therapies</li> <li>• New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> </ul>
<b>5:00 pm</b>	<b>Product Theater # 1 Reception and View exhibits</b>
<b>SAT APRIL 1</b>	
<b>7:30 am</b>	<b>Breakfast and View Exhibits</b>
<b>8:15 am</b>	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis (PSC)</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Predicting outcomes and Improving Survival in PSC patients</li> <li>• Causes and Markers of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Helping patient cope with Cholestasis and Pruritus</li> </ul>
<b>9:00 am</b>	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• How the COVID pandemic changed America’s drinking habits</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> </ul>
<b>9:30 am</b>	<b>Fluid Management, Ascites and Hepatorenal Syndrome</b> <ul style="list-style-type: none"> <li>• The diagnosis and treatment of ascites</li> <li>• How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome</li> <li>• New and emerging treatment approaches for of HRS</li> </ul>

<b>10:00 Am</b>	<b>Break &amp; View Exhibits</b>
<b>10:15 am</b>	<b>NAFLD and NASH</b> <ul style="list-style-type: none"> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Fatty Liver Disease</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
<b>11:00am</b>	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH</li> </ul>
<b>11:50 am</b>	<b>Closing Comments, Post-test, and Wrap-Up</b> Program adjourns at 12:00 noon
<b>Post-program activities</b>	<b>Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes</b> <b>Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes</b>

**Course Directors:** Paul J. Pockros, MD - Scripps Clinic

**Peer Review:** Tracy Ander, DO - University of Louisville School of Medicine